Early childhood weight status in relation to asthma development in high-risk children - 07/08/11


Abstract |
Background |
Obesity has been proposed to be a risk factor for the development of childhood asthma.
Objective |
We sought to examine weight status from birth to age 5 years in relation to the occurrence of asthma at ages 6 and 8 years.
Methods |
Two hundred eighty-five full-term high-risk newborns with at least 1 asthmatic/atopic parent enrolled in the Childhood Origin of Asthma project were studied from birth to age 8 years. Overweight was defined by weight-for-length percentiles of greater than the 85th percentile before the age of 2 years and a body mass index percentile of greater than the 85th percentile at ages 2 to 5 years.
Results |
No significant concurrent association was found between overweight status and wheezing/asthma occurrence at each year of age. In contrast, longitudinal analyses revealed complex relationships between being overweight and asthma. Being overweight at age 1 year was associated with a decreased risk of asthma at age 6 (odds ratio [OR], 0.32; P = .02) and 8 (OR, 0.35; P = .04) years, as well as better lung function. However, being overweight beyond infancy was not associated with asthma occurrence. In fact, only children who were overweight at age 5 years but not at age 1 year had an increased risk of asthma at age 6 years (OR, 5.78; P = .05).
Conclusion |
In children genetically at high risk of asthma, being overweight at age 1 year was associated with a decreased risk of asthma and better lung function at ages 6 and 8 years. However, being overweight beyond infancy did not have any protective effect and even could confer a higher risk for asthma.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, overweight, children, high-risk birth cohort
Abbreviations used : BMI, COAST, FEV0.5, FEV1, FVC
Plan
Supported by National Institutes of Health grants R01 HL61879 and P01 HL70831 and US Department of Agriculture Hatch Multi-State Grant WIS01228. |
|
Disclosure of potential conflict of interest: R. F. Lemanske is a speaker for Merck, AstraZeneca, Doembecher Children’s Hospital, Washington University, Medicus Group, Park Nicolet Institute, the American College of Allergy, Asthma & Immunology, the LA Allergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children’s Hospital of Minnesota, the Toronto Allergy Society, the American Academy of Allergy, Asthma & Immunology, Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, and New York Presbyterian; has consultant arrangements with AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, and Scienomics; is an author for Up-to-Date; and is a textbook editor for Elsevier. The rest of the authors have declared that they have no conflict of interest. |
Vol 126 - N° 6
P. 1157-1162 - décembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?